SCHEMBL21664075

SCHEMBL21664075

CC[C@H](C)[C@@H]1NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]2CSC(=N2)c2cc(cs2)CC(C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](C(C)C)NC1=O

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NNMT P40261 2/20 0.56
CACNA1B Q00975 1/20 0.51
PLAU P00749 2/20 0.49
ITGB3 P05106 1/20 0.49
ITGB1 P05556 1/20 0.49
ITGAV P06756 1/20 0.49
ITGA5 P08648 1/20 0.49
ITGB5 P18084 1/20 0.49
ELANE P08246 4/20 0.49
CTSG P08311 2/20 0.49
KLKB1 P03952 3/20 0.47
KDM4A O75164 1/20 0.47
FLT1 P17948 1/20 0.47
CD2 P06729 1/20 0.45
CD58 P19256 1/20 0.45
KLK7 P49862 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21663884 0.81 PLAU (0.52) NNMTCACNA1BPLAUELANECTSG
SCHEMBL21664221 0.80 ELANE (0.55) NNMTPLAUITGB3ITGB1ITGAV
SCHEMBL21664077 0.80 NNMT (0.52) NNMTCACNA1BPLAUITGB3ITGB1
SCHEMBL24380225 0.80 CTSG (0.49) CACNA1BPLAUCTSGFLT1
SCHEMBL24380214 0.79 PLAU (0.50) NNMTCACNA1BPLAUELANECTSG
SCHEMBL24380224 0.79 CTSG (0.50) CACNA1BPLAUCTSGFLT1
SCHEMBL21663885 0.78 PLAU (0.49) NNMTCACNA1BPLAUELANECTSG
SCHEMBL24380221 0.76 PLAU (0.44) NNMTCACNA1BPLAUITGB3ITGB1
SCHEMBL24454392 0.75 ITGB3 (0.56) CACNA1BITGB3ITGB1ITGAVITGA5
SCHEMBL23839922 0.75 ITGB3 (0.56) CACNA1BITGB3ITGB1ITGAVITGA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319347-B2 Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound FUJIFILM CORPORATION (JP) 2022-05-03 US disclosed
US-20200040039-A1 PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND FUJIFILM CORPORATION (JP) 2020-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200040039-A1 PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND VIP, NPPA, NGLY1 NNMT 4267/4885CACNA1B 1228/4885PLAU 1151/4885
US-11319347-B2 Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound VIP, NPPA, NGLY1 NNMT 4267/4885CACNA1B 1228/4885PLAU 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.